Loading...

Home
Stock
CMND

CMND Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

3.480

Open

3.240

VWAP

3.18

Vol

1.69M

Mkt Cap

3.20M

Low

2.920

Amount

5.37M

EV/EBITDA(TTM)

--

Total Shares

1.02M

EV

-10.07M

EV/OCF(TTM)

--

P/S(TTM)

--

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

Show More

Events Timeline

(ET)

2026-06-16

08:00:00

Clearmind Medicine Completes Dosing for All Participants in CMND-100 Trial

2026-05-26 (ET)

2026-05-26

08:40:00

Clearmind Medicine Receives Approval from Johns Hopkins for CMND-100 Clinical Trial

2026-05-21 (ET)

2026-05-21

11:30:00

Enveric Biosciences Reports Q1 Earnings with Cash Balance of Approximately $10.3M

2026-05-18 (ET)

2026-05-18

09:00:00

Clearmind Signs Research Agreement with Hebrew University

2026-05-14 (ET)

2026-05-14

11:20:00

GH Research Reports Q1 Loss of 26 Cents, Cash at $267.3M

News

Newsfilter

06-16Newsfilter

PinnedClearmind Completes Dosing for Phase I/II Trial of CMND-100

Clinical Trial Progress: Clearmind Medicine Inc. has successfully completed dosing for all 24 participants in its CMND-100 drug trial, marking the completion of Part A of its Phase I/II clinical trial, indicating the company's potential in treating Alcohol Use Disorder.
Recruitment Efficiency: The trial is conducted at multiple clinical centers, including Yale School of Medicine and Johns Hopkins University, with all sites demonstrating rapid patient recruitment and efficient treatment timelines, showcasing the company's execution capabilities in clinical settings.
Positive Safety Results: Interim results indicate a strong safety profile from the first three cohorts, providing confidence for the company as it advances this important program under FDA oversight, potentially paving the way for future drug approvals.
Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, enhancing its competitive position in the neuroplastogen drug market.

NASDAQ.COM

06-05NASDAQ.COM

Biotech Stocks Show Significant Pre-Market Movements

Significant Pre-Market Gains: Bio Green Med Solution, Inc. (BGMS) surged 182% to $3.01 in pre-market trading, indicating strong market reaction to potential acquisition agreements, which may attract further investor interest.
Other Gaining Stocks: Clearmind Medicine Inc. (CMND) rose 37% to $4.03, while BioCardia, Inc. (BCDA) increased by 30% to $1.19, suggesting that financing deals are boosting investor confidence in the biotech sector, potentially leading to a surge in subsequent investments.
Pre-Market Decliners: Indaptus Therapeutics, Inc. (INDP) fell 36% to $3.04, reflecting market concerns over its financial health, which may prompt investors to reassess its future outlook.
Other Declining Stocks: Zhongchao Inc. (ZCMD) dropped 16% to $0.03, and Aditxt, Inc. (ADTX) decreased by 14% to $0.06, indicating a weakening market confidence in these companies, which could impact their future financing capabilities.

Newsfilter

06-05Newsfilter

Clearmind Medicine to Host Webinar on MEAI Clinical Data

Webinar Announcement: Clearmind Medicine Inc. will host a webinar on June 10, 2026, featuring researchers from Yale and Johns Hopkins, aimed at sharing the latest clinical data on CMND-100 for Alcohol Use Disorder, which is expected to attract broad public participation.
Clinical Trial Progress: The ongoing FDA-approved Phase I/IIa multi-center trial evaluating the efficacy of the non-hallucinogenic drug CMND-100 shows potential therapeutic value for Alcohol Use Disorder, potentially addressing significant under-treated health issues.
Expert Lineup: The webinar will feature Dr. Anahita Bassir Nia from Yale and Dr. Jennifer Ellis from Johns Hopkins, both of whom have extensive research experience in psychedelics and novel therapeutics, enhancing the professionalism and authority of the session.
Company Strategic Goals: Clearmind is focused on developing non-hallucinogenic neuroplastogen-derived therapeutics, currently holding 19 patent families and 31 granted patents, with plans to expand its intellectual property portfolio to support long-term growth in the mental health sector.

NASDAQ.COM

06-01NASDAQ.COM

Replimune Receives FDA Support for BLA Resubmission

BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.

stocktwits

05-29stocktwits

Clearmind Secures Patent and Clinical Approval for Alcohol Use Disorder Treatment

Patent Progress: Clearmind's patent application in Japan covers its proprietary MEAI formulation, which is being utilized to develop therapies for depression, weight loss, and alcohol use disorder, potentially enhancing its competitive edge in the biotech sector.
Clinical Trial Approval: Earlier this week, Clearmind received approval from the Johns Hopkins Medicine Institutional Review Board to conduct a Phase I/II clinical trial for CMND-100, an MEAI-based oral candidate targeting alcohol use disorder, which has shown good safety and tolerability.
Stock Surge: Following the patent announcement, Clearmind's shares soared approximately 40% on Friday, marking the largest single-day gain since the company executed a 1-for-10 reverse stock split, reflecting strong market interest in its new therapies.
Investor Sentiment Shift: According to Stocktwits data, retail investor sentiment flipped from 'bearish' to 'extremely bullish' within a day, with extremely high message volumes indicating optimism about Clearmind's future performance, potentially driving the stock price past $10.

Newsfilter

05-29Newsfilter

Clearmind Files Japanese Patent Application, Strengthening Antidepressant Development

Patent Application Filed: Clearmind Medicine Inc. has announced the publication of a Japanese patent application for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, further strengthening its global intellectual property portfolio, which includes 31 granted patents.
Significant Market Potential: The global market for anxiety and depression treatments is projected to reach $19-30 billion by 2030-2031, driven by rising mental health awareness and demand for innovative therapies, positioning Clearmind's MEAI molecule favorably in this rapidly growing sector.
Demand in Japan: With approximately 3 million diagnosed cases of Major Depressive Disorder (MDD) in Japan, exacerbated by societal factors like work-related stress, Clearmind's MEAI offers a safer treatment alternative, addressing the increasing demand in this market.
Pipeline Expansion: Clearmind is expanding its MEAI-based pipeline to include research into alcohol use disorder and metabolic conditions, thereby reinforcing its market position in the neuroplastogen and mental health therapeutics space.

Valuation Metrics

The current forward P/E ratio for Clearmind Medicine Inc (CMND.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Clearmind Medicine Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

good penny stocks soon to blow up

Intellectia · 26 candidates

Market Cap: <= 300.00MPrice: $0.50 - $5.00Volume: >= 500,000Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA60, PriceCrossAboveMA20

Ticker

Name

Market Cap$

Vivos Therapeutics Inc

12.01M

Eastern International Ltd

15.53M

BioCardia Inc

11.72M

YXT.Com Group Holding Ltd

32.36M

Scage Future

61.22M

Galaxy Payroll Group Ltd

6.62M

what stocks are falling today

Intellectia · 2580 candidates

Price Change Pct: <= $0.00

Ticker

Name

Market Cap$

Bitcoin Depot Inc

32.61M

Lichen International Ltd

137.90M

Gossamer Bio Inc

79.80M

WORK Medical Technology Group Ltd

11.49M

Concorde International Group Ltd

290.54M

NeoVolta Inc

109.34M

Intellectia · 16 candidates

Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Outlook Therapeutics Inc

32.35M

Theriva Biologics Inc

11.80M

Cango Inc

198.55M

Silo Pharma Inc

8.38M

Blink Charging Co

99.60M

Cue Biopharma Inc

59.20M

cheapest top moving penny stocks

Intellectia · 16 candidates

Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Enveric Biosciences Inc

4.44M

Theriva Biologics Inc

11.80M

Clearmind Medicine Inc

2.00M

Cue Biopharma Inc

59.20M

Cango Inc

198.55M

TScan Therapeutics Inc

67.71M

stocks under $5 likely to be bullish today

Intellectia · 30 candidates

Price: $0.50 - $5.00Rsi Category: moderatePrice Change Pct: >= $2.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00

Ticker

Name

Market Cap$

JE Cleantech Holdings Ltd

5.26M

Southland Holdings Inc

66.02M

ioneer Ltd

275.18M

Rezolve AI PLC

949.87M

Baozun Inc

121.73M

Skillsoft Corp

34.60M

Low float stock screener

Intellectia · 1484 candidates

List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

Lion Group Holding Ltd

638.91K

La Rosa Holdings

711.55K

Erayak Power Solution Group Inc

831.04K

NewGenIvf Group Ltd

864.77K

Quhuo Ltd

948.08K

Biodexa Pharmaceuticals PLC

1.01M

Find stocks with low float

Intellectia · 2888 candidates

Region: USShares Outstanding: <= 150,000,000

Ticker

Name

Market Cap$

Aditxt Inc

2.59M

Greenwave Technology Solutions Inc

4.33M

Golden Heaven Group Holdings Ltd

5.19M

American Rebel Holdings Inc

3.47M

iPower Inc

5.62M

UTime Ltd

1.44M

Whales Holding CMND

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Clearmind Medicine Inc (CMND) stock price today?

The current price of CMND is 3.14 USD — it has decreased -6.82

What is Clearmind Medicine Inc (CMND)'s business?

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

What is the price predicton of CMND Stock?

Wall Street analysts forecast CMND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMND is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clearmind Medicine Inc (CMND)'s revenue for the last quarter?

Clearmind Medicine Inc revenue for the last quarter amounts to -1.57M USD, increased 20.22

What is Clearmind Medicine Inc (CMND)'s earnings per share (EPS) for the last quarter?

Clearmind Medicine Inc. EPS for the last quarter amounts to -2418081.00 USD, increased 86.24

How many employees does Clearmind Medicine Inc (CMND). have?

Clearmind Medicine Inc (CMND) has 4 emplpoyees as of June 17 2026.

What is Clearmind Medicine Inc (CMND) market cap?

Today CMND has the market capitalization of 3.20M USD.